Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to:
1. establish the safety and dose limiting toxicities of combining alemtuzumab with CHOP
chemotherapy for patients with newly diagnosed aggressive T-cell lymphomas; and
2. to measure the pharmacokinetics of alemtuzumab used in different subcutaneous doses and
schedules.
This will then determine the dose with the highest achievable drug levels with acceptable
toxicities worthy of further investigation.
The secondary objectives are to:
1. establish the efficacy of combination alemtuzumab with CHOP chemotherapy; and
2. to measure the effects of combination alemtuzumab with CHOP chemotherapy on T-cell
reconstitution and cytomegalovirus (CMV) reactivation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ontario Clinical Oncology Group (OCOG)
Collaborators:
Genzyme, a Sanofi Company Sunnybrook Health Sciences Centre